SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Indoco Remedies zooms on getting USFDA’s nod for Apixaban Tablets

14 Sep 2020 Evaluate

Indoco Remedies is currently trading at Rs. 232.00, up by 10.80 points or 4.88% from its previous closing of Rs. 221.20 on the BSE.

The scrip opened at Rs. 220.70 and has touched a high and low of Rs. 234.00 and Rs. 220.70 respectively. So far 12494 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 2 has touched a 52 week high of Rs. 285.00 on 13-Apr-2020 and a 52 week low of Rs. 133.10 on 11-Oct-2019.

Last one week high and low of the scrip stood at Rs. 237.10 and Rs. 213.60 respectively. The current market cap of the company is Rs. 2109.32 crore.

The promoters holding in the company stood at 58.69%, while Institutions and Non-Institutions held 16.54% and 24.77% respectively.

Indoco Remedies has received approval from US Food and Drug Administration (USFDA) for its ANDA for Apixaban Tablets 2.5mg & 5mg. The products are therapeutically equivalent to the Reference Listed Drug ‘Eliquis’ of Bristol-Myers Squibb (BMS). Apixaban is an anticoagulant, or blood thinner. It is used for patients with health problems caused by a blood clot. The US market size of Apixaban Tablets is $11,037 million as per IMS MAT June 2020 data.

Indoco Remedies is engaged in the manufacturing and marketing of formulations (finished dosage forms) and active pharmaceutical ingredients (APIs) in India.

Indoco Remedies Share Price

228.20 -23.05 (-9.17%)
08-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1847.30
Dr. Reddys Lab 1293.25
Cipla 1347.70
Zydus Lifesciences 938.90
Lupin 2377.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×